Continued Late Conversion to Complete Remission (cr/cru) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-Klh, FavId®) Active Immunotherapy.

Background: We have previously reported results from a Phase 2 trial in which both treatment naïve (TN) and relapsed/refractory (R/R) pts with stable disease (SD) or a clinical response (PR or CR/CRu) following 4 weekly doses of rituximab received mitumprotimut-T active immunotherapy (Koc et al, Blood 2006; 108: #691). We report here 4-year follow up of conversion of pts into complete remission (CR/CRu) and an assessment of the DUR in this population.